Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 12:00 p.m. PT / 3:00 p.m. ET in San Francisco.
The company said the live presentation and replay will be available on its investor Events page at https://investors.lexpharma.com/.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, LXRX gained 2.63%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.5% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $447M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves today: gains in AURA, ATXS, INBX and SLDB, alongside a decline in FULC (-7.16%), suggesting stock-specific rather than broad sector momentum. FULC also reported J.P. Morgan conference participation, echoing LXRX’s theme.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Preclinical data | Positive | +0.8% | Publication of ACSL5 preclinical data supporting LX9851’s scientific rationale. |
| Dec 05 | Clinical presentation | Positive | -1.4% | Upcoming sotagliflozin adipose distribution data presentation at CVCT 2025. |
| Nov 25 | Investor conferences | Neutral | -0.7% | December investor conference appearances with webcast access for investors. |
| Nov 11 | Investor conference | Neutral | +9.9% | Jefferies London Healthcare Conference fireside chat announcement. |
| Nov 06 | Earnings/R&D update | Positive | +3.6% | Q3 2025 financial results and broad pipeline progress, including LX9851 and SONATA-HCM. |
Recent history shows generally positive alignment between upbeat news (preclinical data, conferences, earnings) and modest price gains, but data-focused clinical presentations have occasionally seen negative reactions.
Over the past few months, Lexicon reported Q3 2025 results with revenue of $14.2M and an improved net loss of $12.8M, supported by a Novo Nordisk upfront payment and INPEFA sales. It highlighted pipeline progress, including LX9851 and pilavapadin, and announced multiple conference participations and a preclinical LX9851 publication on Dec 10, 2025. Today’s J.P. Morgan conference appearance fits this pattern of ongoing investor and scientific outreach rather than a new financial or clinical inflection point.
Market Pulse Summary
This announcement highlights Lexicon’s participation in the 44th Annual J.P. Morgan Healthcare Conference on January 15, continuing a pattern of active engagement with investors and the healthcare community. Recent history includes Q3 2025 financial improvements, preclinical ACSL5 data for LX9851, and multiple conference appearances. Investors may monitor future updates on pipeline progress, licensing collaborations, and any new financial disclosures emerging from these investor interactions.
AI-generated analysis. Not financial advice.
THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco.
The live event and replay of the presentations can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
When will Lexicon Pharmaceuticals (LXRX) present at the J.P. Morgan Healthcare Conference in 2026?
How can investors watch the Lexicon (LXRX) presentation at the J.P. Morgan Healthcare Conference?
What time is Lexicon (LXRX) presenting in Eastern Time at the J.P. Morgan Healthcare Conference?
Will Lexicon (LXRX) provide a replay of its J.P. Morgan Healthcare Conference presentation?
Where is the 44th Annual J.P. Morgan Healthcare Conference being held where Lexicon (LXRX) will present?
Does Lexicon (LXRX) require registration to view the J.P. Morgan Healthcare Conference presentation?
